The parametric response map is an imaging biomarker for early cancer treatment outcome
- 19 April 2009
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 15 (5), 572-576
- https://doi.org/10.1038/nm.1919
Abstract
In this study, Galbán and his colleagues describe a voxel-wise approach for the quantification of tumor microvasculature properties from perfusion magnetic resonance imaging data. When compared to the standard method of using region of interest analysis of changes in relative cerebral blood flow and volume, the parametric response map approach was found to be more predictive of treatment outcomes and overall survival in individuals with high-grade glioma. Here we describe the parametric response map (PRM), a voxel-wise approach for image analysis and quantification of hemodynamic alterations during treatment for 44 patients with high-grade glioma. Relative cerebral blood volume (rCBV) and flow (rCBF) maps were acquired before treatment and after 1 and 3 weeks of therapy. We compared the standard approach using region-of-interest analysis for change in rCBV or rCBF to the change in perfusion parameters on the basis of PRM (PRMrCBV and PRMrCBF) for their accuracy in predicting overall survival. Neither the percentage change of rCBV or rCBF predicted survival, whereas the regional response evaluations made on the basis of PRM were highly predictive of survival. Even when accounting for baseline rCBV, which is prognostic, PRMrCBV proved more predictive of overall survival.This publication has 33 references indexed in Scilit:
- Comparison of region-of-interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomasJournal of Magnetic Resonance Imaging, 2007
- DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agentsBritish Journal of Cancer, 2007
- The Functional Diffusion Map: An Imaging Biomarker for the Early Prediction of Cancer Treatment OutcomeNeoplasia, 2006
- Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast CancerJournal of Clinical Oncology, 2006
- Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical ResultsJournal of Clinical Oncology, 2005
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I StudyJournal of Clinical Oncology, 2005
- Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumoursEuropean Journal Of Cancer, 2005
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I StudiesJournal of Clinical Oncology, 2003
- High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysisMagnetic Resonance in Medicine, 1996